Menu Search
Equities

I-Mab

IMAB:NMQ

I-Mab

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.09
  • Today's Change0.000 / 0.00%
  • Shares traded101.29k
  • 1 Year change-17.42%
  • Beta1.0656
Data delayed at least 15 minutes, as of Sep 18 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year I-Mab grew revenues -- from -32.93m to 3.90m while net income improved from a loss of 372.62m to a smaller loss of 207.00m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2023, cash reserves at I-Mab fell by 156.82m. However, Cash Flow from Investing totalled 14.48m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 184.30m for operations while cash generated from financing totalled 1.07m.
Cash flow per share--
Price/Cash flow per share--
Book value per share2.91
Tangible book value per share2.91
More ▼

Balance sheet in USDView more

I-Mab appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio16.50
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.